Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

SARS-CoV-2 Infection and Severity in Patients with Hematologic Malignancies: A Systematic Review

Author(s): SeyedAhmad SeyedAlinaghi, Amirali Karimi, Pegah Mirzapour, Roghayeh Salmani, Armin Razi, Hengameh Mojdeganlou, Paniz Mojdeganlou, Mohammad Qodrati, Reyhaneh Jashaninejad, Parinaz Paranjkhoo, Omid Dadras, Besharat Zarezadeh, Amir Masoud Afsahi, Arian Afzalian, Sanaz Varshochi, Esmaeil Mehraeen* and Ghazaleh Afsahi

Volume 23, Issue 7, 2023

Published on: 22 June, 2023

Article ID: e020523216435 Pages: 10

DOI: 10.2174/1871526523666230502142256

Price: $65

Abstract

Introduction: Earlier reports described the possibility of higher SARS-CoV-2 infection and severity in patients with hematological malignancies. Given the importance and incidence of these malignancies, we aimed to systematically review SARS-CoV-2 infection and severity in patients with hematologic cancers.

Methods: We retrieved the relevant records by searching the keywords in online databases of PubMed, Web of Science, Cochrane, and Scopus on December 31st, 2021. A two-step screening; title/abstract and full-text screening, was employed to select the eligible studies. These eligible studies entered the final qualitative analysis. The study is adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist to ensure the reliability and validity of the results.

Results: Forty studies concerning different hematologic malignancies and the effect of COVID-19 infection on them were included in the final analysis. The findings showed that in general, the prevalence of SARS-CoV-2 infection and the severity of the disease are often higher in hematologic malignancies and the patients could experience higher morbidity and mortality compared to general populations.

Conclusion: It appeared that individuals with hematologic malignancies are more vulnerable to COVID-19 infection and they experience more severe disease with higher mortality rates. The presence of other comorbidities could also deteriorate this situation. Further investigation is recommended to evaluate the outcome of COVID-19 infection in different subtypes of hematologic malignancies.

Graphical Abstract

[1]
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727-33.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]
[2]
Mehraeen E, Dadras O, Afsahi AM, et al. Vaccines for COVID-19: A systematic review of feasibility and effectiveness. Infect Disord Drug Targets 2022; 22(2): e230921196758.
[http://dx.doi.org/10.2174/1871526521666210923144837] [PMID: 34554905]
[3]
SeyedAlinaghi S, Karimi A, Mojdeganlou H, et al. Minimum infective dose of severe acute respiratory syndrome coronavirus 2 based on the current evidence: A systematic review. SAGE Open Med 2022; 10.
[http://dx.doi.org/10.1177/20503121221115053] [PMID: 35983085]
[4]
Oliaei S, Seyed Alinaghi S, Mehrtak M. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): A systematic review. Eur J Med Res 2021; 26(1): 96.
[5]
Mehraeen E, Najafi Z, Hayati B, et al. Current treatments and therapeutic options for COVID-19 patients: A systematic review. Infect Disord Drug Targets 2022; 22(1): e260721194968.
[http://dx.doi.org/10.2174/1871526521666210726150435] [PMID: 34313204]
[6]
SeyedAlinaghi S, Karimi A, Barzegary A, et al. Mucormycosis infection in patients with COVID‐19: A systematic review. Health Sci Rep 2022; 5(2): e529.
[http://dx.doi.org/10.1002/hsr2.529] [PMID: 35252593]
[7]
Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91-5.
[http://dx.doi.org/10.1016/j.ijid.2020.03.017] [PMID: 32173574]
[8]
Meng Y, Lu W, Guo E, et al. Cancer history is an independent risk factor for mortality in hospitalized COVID-19 patients: A propensity score-matched analysis. J Hematol Oncol 2020; 13(1): 75.
[http://dx.doi.org/10.1186/s13045-020-00907-0] [PMID: 32522278]
[9]
Yu J, Ouyang W, Chua M, Xie C. SARS-CoV-2 transmission in cancer patients of a tertiary hospital in Wuhan. JAMA Oncol 2020; 6(7): 1108-10.
[10]
Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol 2020; 21(7): 904-13.
[http://dx.doi.org/10.1016/S1470-2045(20)30310-7] [PMID: 32479787]
[11]
Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): A cohort study. Lancet 2020; 395(10241): 1907-18.
[http://dx.doi.org/10.1016/S0140-6736(20)31187-9] [PMID: 32473681]
[12]
Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020; 26(8): 1218-23.
[http://dx.doi.org/10.1038/s41591-020-0979-0] [PMID: 32581323]
[13]
Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: A retrospective study at a major cancer center. Medicine 2006; 85(5): 278-87.
[http://dx.doi.org/10.1097/01.md.0000232560.22098.4e] [PMID: 16974212]
[14]
Garnica M, Maiolino A. COVID and hematology: Special considerations regarding patient safety, gold standard therapies and safety for health care professionals. Hematol Transfus Cell Ther 2020; 42(2): 111-2.
[15]
Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol 2020; 21(3): 335-7.
[http://dx.doi.org/10.1016/S1470-2045(20)30096-6] [PMID: 32066541]
[16]
Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood 2020; 136(25): 2881-92.
[http://dx.doi.org/10.1182/blood.2020008824] [PMID: 33113551]
[17]
Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol 2020; 7(10): e737-45.
[http://dx.doi.org/10.1016/S2352-3026(20)30251-9] [PMID: 32798473]
[18]
Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov 2020; 10(6): 783-91.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0422] [PMID: 32345594]
[19]
Mehta V, Goel S, Kabarriti R, et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov 2020; 10(7): 935-41.
[http://dx.doi.org/10.1158/2159-8290.CD-20-0516] [PMID: 32357994]
[20]
He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia 2020; 34(6): 1637-45.
[http://dx.doi.org/10.1038/s41375-020-0836-7] [PMID: 32332856]
[21]
Cuneo A, Scarfò L, Reda G, et al. Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report. Blood 2020; 136(6): 763-6.
[http://dx.doi.org/10.1182/blood.2020006854] [PMID: 32559271]
[22]
Demichelis-Gómez R, Alvarado-Ibarra M, Vasquez-Chávez J, et al. Treating acute leukemia during the COVID-19 pandemic in an environment with limited resources: A multicenter experience in four latin american countries. JCO Glob Oncol 2021; 7(7): 577-84.
[http://dx.doi.org/10.1200/GO.20.00620] [PMID: 33891480]
[23]
Monika E, Khalid S, Amelie R, et al. Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany. Haematologica 2020; 105(12): 2872-8.
[http://dx.doi.org/10.3324/haematol.2020.262758] [PMID: 33256391]
[24]
Lamure S, Duléry R, Di Blasi R, et al. Determinants of outcome in COVID-19 hospitalized patients with lymphoma: A retrospective multicentric cohort study. EClinicalMedicine 2020; 27: 100549.
[http://dx.doi.org/10.1016/j.eclinm.2020.100549] [PMID: 33073216]
[25]
Martínez-López J, Mateos MV, Encinas C, et al. Multiple myeloma and SARS-CoV-2 infection: Clinical characteristics and prognostic factors of inpatient mortality. Blood Cancer J 2020; 10(10): 103.
[http://dx.doi.org/10.1038/s41408-020-00372-5] [PMID: 33077708]
[26]
Sánchez-Velázquez A, Bauer-Alonso A, Estrach T, et al. Patients with primary cutaneous lymphoma are at risk for severe COVID‐19. J Eur Acad Dermatol Venereol 2021; 35(10): e624-6.
[http://dx.doi.org/10.1111/jdv.17430] [PMID: 34062018]
[27]
Sun C, Li J, Xiang H, et al. COVID-19 in patients with multiple myeloma: A cross-sectional survey from the most severely affected region in China. Leuk Lymphoma 2021; 62(3): 731-4.
[http://dx.doi.org/10.1080/10428194.2020.1834098] [PMID: 33269626]
[28]
Wilde L, Binder AF, Carabasi M, et al. COVID-19 in patients with hematologic malignancies: A single-center experience. Blood 2020; 136 (Suppl. 1): 36-7.
[http://dx.doi.org/10.1182/blood-2020-140719]
[29]
Tailor IK, Alshehry NF, Sabir K, et al. Outcomes of patients of eastern mediterranean region with lymphoma and COVID-19. Does recent chemo immunotherapy have a role on severity? Blood 2020; 136 (Suppl. 1): 25.
[http://dx.doi.org/10.1182/blood-2020-140685]
[30]
Chiaretti S, Bonifacio M, Agrippino R, Annunziata M, Candoni A, Cerrano M, et al. Acute lymphoblastic leukemia (all) and COVID-19 infection. A report from the campus all. Haematologica 2021; 106(10): 50.
[PMID: 35443561]
[31]
Başcı S, Ata N, Altuntaş F, et al. Patients with hematologic cancers are more vulnerable to COVID-19 compared to patients with solid cancers. Intern Emerg Med 2022; 17(1): 135-9.
[PMID: 34110562]
[32]
Bonifacio M, Tiribelli M, Miggiano MC, et al. The serological prevalence of SARS‐CoV‐2 infection in patients with chronic myeloid leukemia is similar to that in the general population. Cancer Med 2021; 10(18): 6310-6.
[http://dx.doi.org/10.1002/cam4.4179] [PMID: 34464516]
[33]
Krejci M, Pour L, Adam Z, et al. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: Single-center experience. Ann Hematol 2021; 100(10): 2541-6.
[http://dx.doi.org/10.1007/s00277-021-04594-w] [PMID: 34309714]
[34]
Pagnano KB, Peralta EH, Navarro JR, et al. COVID-19 in chronic myeloid leukemia patients in Latin America. Leuk Lymphoma 2021; 62(13): 3212-8.
[http://dx.doi.org/10.1080/10428194.2021.1950709] [PMID: 34254886]
[35]
Palanques-Pastor T, Megías-Vericat JE, Martínez P, et al. Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: Experience of the PETHEMA group. Leuk Lymphoma 2021; 62(12): 2928-38.
[http://dx.doi.org/10.1080/10428194.2021.1948031] [PMID: 34292118]
[36]
Rajic J, Gmizic I, Gunjak T, et al. COVID-19-associated pulmonary aspergillosis in patients with acute leukemia: A single-center study. J Fungi 2021; 7(11): 890.
[http://dx.doi.org/10.3390/jof7110890] [PMID: 34829179]
[37]
Stahl M, Narendra V, Jee J, et al. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leuk Lymphoma 2021; 62(8): 1940-8.
[http://dx.doi.org/10.1080/10428194.2021.1885664] [PMID: 34180767]
[38]
Wang XA, Binder AF, Gergis U, Wilde L. COVID-19 in patients with hematologic malignancies: A single center retrospective study. Front Oncol 2021; 11: 740320.
[http://dx.doi.org/10.3389/fonc.2021.740320] [PMID: 34778057]
[39]
Wang L, Berger NA, Xu R. Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma. JAMA Netw Open 2021; 4(11): e2137575.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.37575] [PMID: 34812850]
[40]
Anusim N, Smalley M, Zimmer MS, et al. COVID-19 and hematologic malignancies: Single institution analysis. Blood 2020; 136 (Suppl. 1): 27.
[http://dx.doi.org/10.1182/blood-2020-142784]
[41]
Behrens E, Timmermann A, Yerkan A, et al. Outcomes of COVID-19 infection in patients with hematologic malignancies. Blood 2020; 136 (Suppl. 1): 20-1.
[http://dx.doi.org/10.1182/blood-2020-141063]
[42]
Blixt L, Bogdanovic G, Buggert M, et al. COVID-19 in patients with chronic lymphocytic leukemia: Clinical outcome and B- and T-cell immunity during 13 months in consecutive patients. Leukemia 2022; 36(2): 476-81.
[PMID: 34564699]
[43]
Bonifacio M, Binotto G, Tiribelli M, et al. Serological prevalence of SARS-CoV-2 infection among chronic myeloid leukemia patients undergoing tyrosine kinase inhibitor treatment in Italy (COVID-19-HEM Study). Blood 2020; 136 (Suppl. 1): 42.
[http://dx.doi.org/10.1182/blood-2020-140032]
[44]
Breccia M, Abruzzese E, Bocchia M, et al. Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia 2020; 34(8): 2260-1.
[http://dx.doi.org/10.1038/s41375-020-0904-z] [PMID: 32555369]
[45]
Duléry R, Lamure S, Delord M, et al. Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy. Am J Hematol 2021; 96(8): 934-44.
[http://dx.doi.org/10.1002/ajh.26209] [PMID: 33909916]
[46]
Scarfò L, Chatzikonstantinou T, Rigolin GM, et al. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: A joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia 2020; 34(9): 2354-63.
[http://dx.doi.org/10.1038/s41375-020-0959-x] [PMID: 32647324]
[47]
Li W, Wang D, Guo J, et al. COVID-19 in persons with chronic myeloid leukaemia. Leukemia 2020; 34(7): 1799-804.
[http://dx.doi.org/10.1038/s41375-020-0853-6] [PMID: 32424293]
[48]
Chhabra S, Dabas A, Mittal R, et al. Retrospective review of SARS-CoV2 infection in children withacute leukemia from a tertiary hospital in Northern India. Clin Exp Pediatr 2021.
[49]
Regalado-Artamendi I, Sanchez GP, Velasco A, et al. Lymphoma and COVID-19, impact of the pandemic in a high incidence area. Multicentric study of the community of madrid. Haematologica 2020; 105: 332-3.
[50]
Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set. Blood 2020; 136(26): 3033-40.
[http://dx.doi.org/10.1182/blood.2020008150] [PMID: 33367546]
[51]
Wang B, Van Oekelen O, Mouhieddine TH, et al. A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. J Hematol Oncol 2020; 13(1): 94.
[http://dx.doi.org/10.1186/s13045-020-00934-x] [PMID: 32664919]
[52]
Ribera JM, Morgades M, Coll R, et al. Frequency, clinical characteristics and outcome of adults with acute lymphoblastic leukemia and COVID-19 infection in the first vs. second pandemic wave in Spain. Clin Lymphoma Myeloma Leuk 2021; 21(10): e801-9.
[http://dx.doi.org/10.1016/j.clml.2021.06.024] [PMID: 34376375]
[53]
Hultcrantz M, Richter J, Rosenbaum CA, et al. COVID-19 infections and clinical outcomes in patients with multiple myeloma in New York City: A cohort study from five academic centers. Blood Cancer Discov 2020; 1(3): 234-43.
[http://dx.doi.org/10.1158/2643-3230.BCD-20-0102] [PMID: 34651141]
[54]
Lins MM, Costa JT, Wanderley AV, et al. Successful outcomes of children simultaneously diagnosed with acute myeloid leukemia and COVID-19: The role of a mild chemotherapeutic induction regimen. Blood 2020; 136 (Suppl. 1): 3-4.
[http://dx.doi.org/10.1182/blood-2020-143314]
[55]
Galvez C, Nizamuddin I, Tuchman E, et al. Outcomes in patients with hematologic malignancies infected with SARS-CoV-2: The northwestern university experience. Blood 2020; 136 (Suppl. 1): 14-6.
[http://dx.doi.org/10.1182/blood-2020-139495]
[56]
Rubinstein S, Lynch RC, Desai A, et al. Severity of SARS-CoV-2 infection in patients with hematologic malignancies: A COVID-19 and cancer consortium (CCC19) registry analysis. Blood 2020; 136 (Suppl. 1): 28-30.
[http://dx.doi.org/10.1182/blood-2020-141937]
[57]
Colunga-Pedraza JE, Colunga Pedraza PR, Arrieta J, et al. Cancer does not wait: Safeguarding care for pediatric acute lymphoblastic leukemia patients during the COVID‐19 pandemic in a Mexican hospital. Pediatr Blood Cancer 2022; 69(7): e29498.
[http://dx.doi.org/10.1002/pbc.29498] [PMID: 34889042]
[58]
Thompson MA, Henderson JP, Shah PK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol 2021; 7(8): 1167-75.
[http://dx.doi.org/10.1001/jamaoncol.2021.1799] [PMID: 34137799]
[59]
Visco C, Marcheselli L, Mina R, et al. A prognostic model for patients with lymphoma and COVID-19: A multicentre cohort study. Blood Adv 2021.
[PMID: 34644385]
[60]
Wang Q, Berger NA, Xu R. When hematologic malignancies meet COVID-19 in the United States: Infections, death and disparities. Blood Rev 2021; 47: 100775.
[http://dx.doi.org/10.1016/j.blre.2020.100775] [PMID: 33187811]
[61]
Regalado-Artamendi I, Jiménez-Ubieto A, Hernández-Rivas JÁ, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: A multicenter study. HemaSphere 2021; 5(3): e538.
[http://dx.doi.org/10.1097/HS9.0000000000000538] [PMID: 33604516]
[62]
SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID‐19 in HIV‐positive patients: A systematic review of current evidence. Immun Inflamm Dis 2021; 9(4): 1160-85.
[http://dx.doi.org/10.1002/iid3.497] [PMID: 34324280]
[63]
SeyedAlinaghi S, Karimi A, Barzegary A, et al. COVID-19 mortality in patients with immunodeficiency and its predictors: A systematic review. Eur J Med Res 2022; 27(1): 195.
[http://dx.doi.org/10.1186/s40001-022-00824-7] [PMID: 36209202]
[64]
Mehraeen E, Pashaei Z, Khajeh Akhtaran F, et al. Estimating methods of the undetected infections in the COVID-19 outbreak: A systematic review. Infect Disord Drug Targets 2023.
[PMID: 36698234]
[65]
Mehrabi Nejad MM, Moosaie F, Dehghanbanadaki H, et al. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: A systematic review and meta-analysis. Eur J Med Res 2022; 27(1): 23.
[http://dx.doi.org/10.1186/s40001-022-00648-5] [PMID: 35151362]
[66]
Asadollahi-Amin A, Hasibi M, Ghadimi F, Rezaei H. SeyedAlinaghi S. Lung involvement found on chest CT scan in a pre-symptomatic person with SARS-CoV-2 infection: A case report. Trop Med Infect Dis 2020; 5(2): 56.
[http://dx.doi.org/10.3390/tropicalmed5020056] [PMID: 32272630]
[67]
Navari Y, Bagheri AB, Akhavan Rezayat A, et al. Mortality risk factors in kidney‐transplanted patients with COVID ‐19: A systematic review and regression analysis. Health Sci Rep 2021; 4(4): e427.
[http://dx.doi.org/10.1002/hsr2.427] [PMID: 34761124]
[68]
Ghiasvand F. A patient with COVID-19 pneumonia presenting with plural effusion: A case report. Infect Disord Drug Targets 2021; 21(6): 77-80.
[69]
Mehraeen E, Karimi A, Barzegary A, et al. Predictors of mortality in patients with COVID-19–a systematic review. Eur J Integr Med 2020; 40: 101226.
[http://dx.doi.org/10.1016/j.eujim.2020.101226] [PMID: 33101547]
[70]
Predictors of the prolonged recovery period in COVID-19 patients: A cross-sectional study. Eur J Med Res 2021; 26(1): 1-10.
[PMID: 33388089]
[71]
Dadras O, Afsahi AM, Pashaei Z, et al. The relationship between COVID‐19 viral load and disease severity: A systematic review. Immun Inflamm Dis 2022; 10(3): e580.
[http://dx.doi.org/10.1002/iid3.580] [PMID: 34904379]
[72]
Mehrabi Nejad MM, Shobeiri P, Dehghanbanadaki H, et al. Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: A systematic review and meta-analysis. Virol J 2022; 19(1): 132.
[http://dx.doi.org/10.1186/s12985-022-01858-3] [PMID: 35941646]
[73]
Mehraeen E, Salehi MA, Behnezhad F, Moghaddam HR. SeyedAlinaghi S. Transmission modes of COVID-19: A systematic review. Infect Disord Drug Targets 2021; 21(6): e170721187995.
[http://dx.doi.org/10.2174/1871526520666201116095934] [PMID: 33200716]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy